Steroidogenesis Inhibitors (STGI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Madeleine Harrison who wrote (112)	7/20/1999 6:58:00 PM
From: Jim Burnham	Read Replies (1) of 294

Las Vegas' STGI Beats the Odds to Become Fully Reporting LAS VEGAS--(BW HealthWire)--July 20, 1999---Alfred T. Sapse, President of Steroidogenesis Inhibitors International (OTC BB:STGI), announced today that the Company has filed a registration statement on Form 10-SB with the United States Securities and Exchange Commission for the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934. The registration statement becomes effective by statute no more than 60 days after its filing. On the effective date, the Company will be a "reporting company" and will accordingly be required to file periodic reports with the Commission. The Commission's web site can be found at www.sec.gov and the Company's registration statement can be found under the EDGAR listing at that web site. The Company's drug ANTICORT(TM) is a dramatic step forward in anti-cortisol technology. ANTICORT is an anti-cortisol, steroidogenesis inhibitor drug for the treatment of immune deficiency in AIDS/HIV and other diseases such as aging and cancer where a high level of the hormone cortisol plays a major role in destroying the immune system. ANTICORT is currently in Clinical Trials, Phase IB/IIA for AIDS/HIV under FDA Regulations. Dr. Sapse stated: "We are committed to building shareholder value and are excited that we expect to be in compliance with OTC Bulletin Board eligibility rules long before the NASD's schedule." For more information visit our World Wide Web page at www.anticort.com. This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. CONTACT: Steroidogenesis Janet Greeson, Ph.D 702/222-1988 or Performance Strategies, Inc. Richard L. Brown / Chuck Jordan 303/948-3601

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next